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Abstract
Objective To examine methods for generating evidence on health
outcomes in patients with rare diseases.
Design Methodological review of existing literature.
Setting PubMed, Embase, and Academic Search Premier searched for
articles describing innovative approaches to randomized trial design and
analysis methods and methods for conducting observational research
in patients with rare diseases.
Main outcome measures We assessed information related to the
proposed methods, the specific rare disease being studied, and outcomes
from the application of the methods. We summarize methods with respect
to their advantages in studying health outcomes in rare diseases and
provide examples of their application.
Results We identified 46 articles that proposed or described methods
for studying patient health outcomes in rare diseases. Articles covered
a wide range of rare diseases and most (72%) were published in 2008
or later. We identified 16 research strategies for studying rare disease.
Innovative clinical trial methods minimize sample size requirements
(n=4) and maximize the proportion of patients who receive active
treatment (n=2), strategies crucial to studying small populations of
patients with limited treatment choices. No studies describing unique
methods for conducting observational studies in patients with rare
diseases were identified.
Conclusions Though numerous studies apply unique clinical trial designs
and considerations to assess patient health outcomes in rare diseases,
less attention has been paid to innovative methods for studying rare
diseases using observational data.
Introduction
Though an individual rare disease is by definition uncommon,
according to the statutory definitions set in the United States
(prevalence<200000peopleeachyear;equatingtoaprevalence
ofapproximately<64per100000people)andEuropeanUnion
(<50 per 100 000 people), more than 6800 different conditions
qualifyasrarediseasesand6-8%ofthepopulationisaffected.
1-3
This translates to about 60 million people in the United States
and EU alone. Rare diseases comprise a heterogeneous set of
conditionsthatafflictvariousorgansystems,havewideranging
prognoses, and even vary along a gradient of rareness.
Many barriers exist to advancing knowledge of and treatment
options for rare diseases.
4 The small patient populations can
dampen commercial interest in development of treatments. Yet
even for those rare conditions where funding is plentiful and
manufacturersoftherapeuticsareengaged,methodologicaland
data constraints limit the ability to generate evidence on patient
health outcomes. The most obvious challenge to conducting
rigorous research is the small number of eligible participants
foragivenstudy.Inaddition,geographicdispersionofpatients,
lackofknowledgeabouttheclinicalcourseofdisease,andlack
of appropriate comparator treatments further hinder the
generation of evidence.
5 As a result relatively little is known
abouttheclinicalcourseofmanyrarediseasesandfewtreatment
options exist.
However,theremaybepathwaysforcollectivelyadvancingthe
study of rare diseases. Although rare diseases may present
unique clinical problems, the methodological challenges to
studying health outcomes are often communal. In recent years,
innovativeepidemiologicalandclinicaltrialmethodshavebeen
developed that offer promise for promoting more efficient and
effective research. Because rare diseases are so clinically
dissimilar,clinicians,scientists,andotherstakeholdersworking
inonemedicalspecialtymaynotbefamiliarwithmethodsbeing
applied in other disciplines. Thus, we conducted a
methodological review to catalogue and describe innovative
approaches to studying health outcomes in patients with rare
diseases. Our goal was to identify innovative approaches to
research that have been, or can be, applied to overcome the
methodologicalchallengesinherentinthestudyofrarediseases.
Correspondence to: J J Gagne jgagne1@partners.org
Extra material supplied by the author (see http://www.bmj.com/content/349/bmj.g6802?tab=related#datasupp)
Details of search strategy
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6802 doi: 10.1136/bmj.g6802 (Published 24 November 2014) Page 1 of 10
Research
RESEARCHMethods
Search strategy
We searched PubMed, Embase, and Academic Search Premier
fromtheircommencementthroughDecember2012forEnglish
language articles that included the following terms: “rare
diseases”, “orphan drug”, “comparative effectiveness”,
“evidence-based medicine”, “health technology assessment”,
“outcome assessment”, “methods”, “epidemiology”, and
“registries”. The supplementary file provides details of the
search strategies.
We also conducted ad hoc searches of the three reference
databases as well as general internet searches in Google using
search terms specific to individual rare diseases (for example,
progeria)andnamesofmethods(forexample,responseadaptive
randomization) identified in the database searches. Finally, we
mined the reference lists of qualifying articles to supplement
our search.
Article selection
We combined the results of each search strategy and removed
duplicates. One author (LT) screened titles and abstracts to
exclude those articles that were clearly not relevant. Another
author(JJG)conductedasecondstagescreeningofthosearticles
that passed the title and abstract screens. We included articles
covering randomized trial design and analysis methods and
methodsforconductingobservationalresearch.Articlesrelating
tootherfacetsofrarediseasesandtheirtreatments(forexample,
those related to clinical practice or policy) were excluded.
Data extraction
We extracted descriptive information about each article,
including information on the authors, title, and publication. If
the article focused on a specific rare disease, we extracted the
nameofthecondition.Wethensummarizedtheuniquemethods
proposedorusedineacharticletostudypatienthealthoutcomes
inrarediseases.Ifthearticlepresentedanempiricalapplication
of an innovative method, we extracted the study’s objective,
the number of participants, the description of the method, and
the description of the outcome.
For the qualitative synthesis, we classified novel research
methods relating to the study of rare diseases into two broad
categories: advances in clinical trial design for patients with
rare diseases, and methods for observational studies of health
outcomes in rare diseases. In each category we highlighted the
most innovative research methodologies, and, where possible,
provided examples of their applications.
Results
We identified 5346 records through our search process. After
removing duplicates and performing an initial title screening to
exclude those that were clearly irrelevant to our review, we
identified 442 potentially relevant articles and, after the
subsequent two stage screening process, we obtained full text
versions of 55 articles. Of these, 46 proposed or employed
methods for studying patient health outcomes in rare diseases
(figure⇓). Articles covered a wide range of rare diseases, from
amyotrophic lateral sclerosis to multiple myeloma to uveal
melanoma. Of the 13 articles that involved an empirical
application,thenumberofparticipantsrangedfrom23to4980.
Mostofthearticles(33/46,70%)werepublishedbetween2008
and2012.Table1⇓presentsasummaryoftheresearchmethods
weidentifiedandtheiradvantagesinthesettingofresearchinto
rare diseases.
Clinical trial designs used in patients with
rare diseases
Conventionalparallelgrouprandomizedcontrolledtrials,which
randomly allocate participants to one of two or more treatment
groups, are not always feasible in rare conditions.
6 We found
19 articles proposing or employing novel clinical trial methods
for studying therapeutic interventions in rare diseases. These
approaches were classified into two groups: designs that
minimize the total number of participants, and designs that
maximize the number of on-treatment participants.
Minimizing trial sample size
Investigators studying rare diseases have tried to deal with the
smallpoolofpotentialtrialparticipants.Someproposedormade
adjustmentstotraditionalrandomizedtrials.Forexample,when
consideringthetreatmentperiod,choosingalongertrialduration
can reduce sample size requirements by capturing more events
amongthetrialparticipants.
7Focusingonhighriskpatientscan
reducesamplesizeandstudyduration,
8andusinggenetictesting
can reduce variability between individuals and allow inclusion
of patients before they experience symptoms.
9 Finally, some
investigators have sought to reduce sample size by tackling
multiple treatment options in a factorial study, in which two (or
more) treatment comparisons are carried out simultaneously.
10
Factorial designs provide answers to multiple questions within
the same study population. This reduces the total number of
patients required to answer all of the questions of interest but
does not reduce the number of patients required to answer each
individual question.
Anotherwaytoreducesamplesizerequirementsinraredisease
studies is through selection of the outcome measure using a
continuous outcome variable, a surrogate marker, a composite
endpoint,orrepeatedmeasureoutcome.Identifyingacontinuous
outcome variable, rather than a binary measure, can enhance
statistical efficiency.
7 For example, percentage reduction in a
continuous measurement imparts greater statistical power in an
analysisthananoutcomemeasurementbasedontheproportion
of patients who attain some threshold in reduction of the
measure, provided that the continuous outcome variable has a
small variance. Surrogate endpoints, such as biomarkers, that
predict whether patients will experience clinical outcomes of
interest may also be useful, but validating biomarkers as good
surrogates of the clinical outcome of interest can be difficult.
They can further enhance statistical power since a potentially
smallnumberofpatientsinastudyexperiencethehardendpoint
of interest, whereas nearly all patients have measured values of
the biomarker.
7 11 When hard clinical endpoints are preferred,
combining multiple outcomes into a single composite outcome
measure can increase the number of observed events and thus
thestatisticalpower.
12Repeatedoutcomemeasurementspermit
patients to contribute more than one outcome event or
measurement,whichalsoincreasesstudypower,allowingmore
preciseestimationofvariancebetweenpatientswhilepermitting
estimation of the variance within patients.
12
Athirdapproachtothesamplesizeproblemistobuildnetworks
to allow broader access to trials. Development of clinical trial
networks for rare diseases can facilitate the conduct of
multicenter and even multinational randomized trials.
13 Trial
networks facilitate the recruitment of larger and more
geographically diverse patient populations than may be
permitted by single center studies.
14 The existence of such
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RESEARCHnetworks can also decrease the time required to complete a
trial.
14 For example, Goss and colleagues provide a
comprehensive overview of clinical trial networks for rare
diseases in the context of the Cystic Fibrosis Therapeutics
Development Network.
14
Finally, we found investigators who proposed and used novel
trialdesignstrategiestoaccountforsmallpoolsofpatientswith
rare diseases. Trials featuring an “adaptive design” allow
modificationofsomeaspectsofthetrialbasedonprospectively
planned interim data analyses. The two basic types of adaptive
designs are adaptive randomization and sequential trials. In
trials using adaptive randomization, the probability of being
randomized to an intervention changes during the enrollment
period.Thegoalofadaptiverandomizationmaybetominimize
imbalance in baseline covariates among treatment groups
(covariate-adaptiverandomization)ortoincreasetheproportion
of patients assigned to the seemingly more effective treatment
while reducing overall trial enrollment (response-adaptive
randomization). By contrast, in sequential trials, data are
analyzed intermittently to guide decisions on termination when
safety concerns, futility, efficacy, or a combination of these
factors is demonstrated. Trials that are stopped early because
of important interim results require fewer patients. However,
to control for multiple testing, trials that are not stopped early
generally require larger sample sizes compared with similarly
designednon-sequentialtrials.Chowandcolleagues,Guptaand
colleagues, and Cornu and colleagues have all summarized
adaptive and sequential design methods in clinical trials and
provideexamplesofapplicationstorarediseases.
15-17Guptaand
colleagues also provide a framework for selecting among these
approaches for studies of rare diseases.
Manyvariantsofadaptiverandomizationandsequentialdesigns
areapplicabletostudyingrarediseasesbecausetheycanreduce
the sample size required for conventional trials. In addition,
certain adaptive designs can also increase participants’
probabilityofreceivingthemosteffectivetreatment,whichcan
encourage enrollment in a trial.
7 11 12 15 16 18 The decision about
whethertouseanadaptivedesigninvolvesconsideringwhether
a set sample size can be reasonably recruited, the number of
therapeutic options to be compared, and whether preliminary
data suggest one treatment is superior.
16 Cornu and colleagues
proposed an algorithm for choosing an experimental design for
small randomized clinical trials that also involves judging
whether the outcome is reversible, whether the treatment
response is likely to be rapid, and whether investigators seek to
minimize the time participants are receiving placebo.
17
Even if investigators use one of these innovative designs or
adaptations of traditional trials in studying a rare disease
treatment, individual trials of patient health outcomes may not
be capable of attaining sufficient power to reject the null
hypothesisusingaconventionalfrequentistthreshold(α=0.05).
One solution is to increase α, as was done in the alternating
design trial of itraconazole by Gallin and colleagues.
19 Another
solution is to conduct the underpowered study and incorporate
the results into a prospectively planned meta-analysis.
18 20 21 A
third option is to incorporate the results into a bayesian
framework. Lilford and colleagues recommend the third
approach for trials in rare diseases in which the individual trials
are unlikely to result in a definitive answer but each can change
thelevelofcertaintyaroundtheclinicalquestion.
22Thebayesian
approach uses all available data—from the trial and other
sources—to calculate probabilities that a particular treatment
is effective. These probabilities can then be applied to clinical
practice. Bayesian methods can also be useful in individual
studies(randomizedcontrolledtrialsandobservational)ofhealth
outcomes in rare diseases.
11
Tanandcolleaguesdescribedabayesianapproachtocombining
previous data with data from a new randomized controlled trial
by creating scores that are then used to weight the pieces of
evidenceaccordingtotheirpertinence,validity,andprecision.
23
The validity scores enable investigators to down-weight
evidence based on studies with flaws or other concerns, such
as confounding in non-randomized trials. Pertinence scores are
based on how closely the information from each source relates
totheinformationtobegainedinthetrial.Intheory,pertinence
scores could also be based on the degree to which the evidence
streams are relevant to patients’ decision making and could
thereforesupportpatientcentereddecisionmaking.Theauthors
make the case that such a bayesian approach can increase the
robustness of information from small trials and can be used to
help design and provide justification for such trials. However,
bayesianapproachesrequireappropriatespecificationofaprior
distribution, which may be subjective or based on limited
information.
Maximizing on-treatment participants
Trials that guarantee participants receive an intervention can
enhance recruitment for patients with rare diseases who have
limitedtreatmentoptions.Someofthesedesignscanalsoreduce
recruitment requirements compared with alternative
conventional parallel group randomized controlled trials. For
example, crossover trials involve randomizing patients to
treatment at one time (or several times) and to no treatment (or
treatment with a comparator) at another time (or other
times).
10 12 13 16 23 24 In addition to guaranteeing treatment,
crossover designs are more statistically efficient than their
parallel group randomized controlled trial counterparts.
Crossover trials are particularly well suited to studying
treatmentsforchronicconditionsinwhichthetreatmentsprovide
immediate relief of symptoms. But crossover trials generally
cannot be used to study treatments that have curative effects or
conditions that are rapidly changing. Many rare diseases are
chronic conditions that progress over time. Changes in the
diseaseovertimethatareunrelatedtothetreatmentunderstudy
can cause bias in crossover trials. Crossover trials also require
a transient treatment effect to minimize carryover effects into
the subsequent treatment periods.
In the most basic crossover design involving two treatments,
patients are randomly assigned to one treatment, followed by a
washout period, and then receive a different treatment. Other
patients are randomized to the reverse ordering. More complex
crossoverstudiesincludesocalledalternatingdesigns,inwhich
patients are randomly assigned to each treatment at multiple
time points.
25 Gallin and colleagues conducted a randomized
crossover trial to examine itraconazole for fungal infections in
patients with chronic granulomatous disease.
19 Given the rarity
of this disease, it took 10 years to enroll only 39 patients. The
investigatorsrandomlyassignedpatientstoreceiveitraconazole
or placebo for one year and then to alternate annually between
itraconazoleandplacebo.Whilethisapproachcouldnotprovide
much information on the long term safety of itraconazole
treatment,themultipleobservationsthateachpatientcontributed
made it possible to achieve sufficient statistical power (defined
as a two sided type I error probability of 0.10) with only 39
participants.
25
An n-of-1 study is a special type of crossover design in which
the trial comprises one patient.
10-13 16 23 24 Within clinical practice
settings, healthcare providers administer a treatment and a
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RESEARCHcontrol at randomly determined times and observe subsequent
outcomes. These trials require the same general assumptions as
crossovertrials.Whilestatisticalinferencecannotbemadebased
on a single n-of-1 trial, results of multiple such studies can be
aggregatedincaseseriesorevenmeta-analyzedquantitatively.
26
Investigators in the Netherlands are developing an n-of-1 trial
service integrated in the Dutch healthcare system to generate
evidence on the efficacy of treatments for rare neuromuscular
diseases.
27 It will involve testing treatments that are available
on the market but not necessarily approved for the
neuromuscularindications.Theprojectwillcreateprotocolsfor
eachn-of-1trialandwillcollectthedatainanelectronicregistry
system.Lesscommonvariantsofcrossoverdesignsincludethe
Latin square design, the stepped wedge design, and the
randomized withdrawal design.
17 Cornu and colleagues and
Gupta and colleagues provide more detailed descriptions of the
application of these clinical trial designs to studying treatments
in rare diseases.
16 17
Methods for observational studies of health
outcomes in rare diseases
In addition to the often small samples, studies using
observational data to assess patient health outcomes in rare
diseases face important challenges. For example, there is often
no appropriate comparison group against which to compare
outcome frequencies in patients with rare diseases and even
when there is, controlling for confounding can be difficult
because the risk factors of those outcomes are usually not well
understood. Table 2⇓ summarizes methods that have been
proposed or used to analyze health outcomes in patients with
rare disease in observational data. These methods can be
generally classified into four categories: advanced methods to
tackleconfounding,selfcontrolledobservationalstudydesigns,
approaches for case-control studies, and prospective inception
cohorts.
Advanced methods to deal with confounding
Some authors have suggested the use of certain advanced
methods to tackle confounding in studies of rare disease health
outcomes, such as propensity scores.
28 29 When comparing
patients being treated for a particular rare disease to patients
with the same disease but who are not being treated,
confounding will occur if the determinants of one patient’s
receipt of treatment over another are also risk factors for the
outcome of interest. Often, many such confounders can be
present. Propensity scores reduce the dimensionality of
confounding in observational studies by summarizing all
potential confounders into a single scalar score.
30 This tool is
particularly useful in studies in which there are few outcome
eventsrelativetothenumberofconfounders,whichisadefining
characteristic of rare diseases.
31 In a study of a dose-response
effect of enzyme replacement therapy in patients with Gaucher
disease type 1, Grabowski and colleagues created propensity
scores to summarize multiple confounders and then used the
scorestomatchpatientswhoreceiveddifferentdosesofenzyme
therapy.
32 Though propensity scores can facilitate adjustment
formanypotentialconfoundersbymodelingtheexposurerather
than the outcome, neither propensity scores nor traditional
outcome regression modeling can overcome confounding due
to unmeasured variables.
Self controlled observational study designs
Self controlled observational designs may be useful in the rare
disease setting. These approaches are observational analogues
to the randomized crossover trials described above in which
patients act as their own controls. These studies can be indexed
by outcome, such as in case-crossover designs,
33 in which the
frequency of exposure is compared during different time points
among those who develop the outcome. They can also be
indexed by exposure, such as the self controlled case series,
34
inwhichthefrequencyofoutcomeiscomparedduringdifferent
timepointsamongthoseexposedtotheinterventionofinterest.
Notable for patients with rare diseases, these approaches are
immunetoconfoundingbyfactorsthatdonotchangeovertime
because of the within person comparisons. Similar to
randomized self controlled trial designs, self controlled
observational methods enhance statistical power and therefore
reduce sample size requirements. Self controlled observational
methods are subject to the same limitations as randomized self
controlled trial designs but can also be susceptible to time
varyingconfounding,suchaswhenworseningofdisease,which
maybeariskfactorfortheoutcomeofinterest,mayalsoprompt
treatment.
Case-control designs
Several observational studies of rare diseases have used a
case-control design, which is particularly useful in settings in
which outcomes are rare and require primary data collection
methods. Case-control studies involve sampling from an
underlying cohort of patients rather than utilizing information
on all cohort patients, which can be resource prohibitive.
Schmidt-Pokrzywniakandcolleaguesconductedaninstitutional
based case-control study to examine risk factors for uveal
melanoma.
35 Rather than using a full cohort approach, the
authorsrecruitedcasesfromareferralcenterforeyetumorsand
sampledcontrolsfromamongthecases’siblingsandfromlocal
ophthalmologists’ case loads. The case-control design yields
anestimateofthesameeffectestimateasiftheentireunderlying
cohort were used, but with slightly less precision given the
sampling. In addition to reducing sample size requirements by
identifying all cases and sampling controls, the case-control
design allows investigators to easily examine multiple risk
factors related to the outcome of interest. In other articles,
Schmidt-Pokrzywniak and colleagues have examined the
relations between uveal melanoma and mobile phone use,
occupational cooking, and ultraviolet radiation.
36-38
Cole and colleagues conducted a case-control study using the
International Collaborative Gaucher Group registry.
28 The
authors compared the odds of splenectomy in patients with
avascular necrosis (cases) with the odds in patients without
avascularnecrosis(controls).Theauthorsusedrisksetmatching,
which can reduce bias in case-control studies relative to other
sampling strategies. In risk set matching, controls are sampled
from sets of patients at risk for the outcome at the time of the
corresponding case event. These sets are usually defined by
calendartimebutcanbedefinedbyothervariablesaswell,such
as age and sex.
Prospective inception cohorts
Afourthgroupofstudiesemployedprospectiveinceptioncohort
designs, which are also sometimes referred to as “new user”
designs when cohort inception is defined by the start of some
medical treatment.
39 40 Inception cohorts permit investigators to
establish clear temporality among study variables (that is,
baseline confounders, exposures, and outcomes) and capture
outcomeeventsthatoccurshortlyafterentrytothecohort.This
approach is particularly important for outcomes related to
medicalinterventionsthatmaybeimmediatelyaffectedbythose
interventions. While inception cohorts increase validity of
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RESEARCHobservational studies, they can be difficult to implement for
rare diseases because they require restricting the already small
patient population to those with an observable start of the
exposure, risk factor, or disease of interest. Identifying patients
at the onset of a rare disease can be challenging because there
can be a long lag time associated with making accurate
diagnosesforrarediseases.Thus,patientsenrollinginregistries
and other data sources may have had the underlying condition
andsubsequenttreatmentforsometime.Inaddition,identifying
“new users” of medical treatments for rare diseases outside of
clinical trials can be limited if a large proportion of patients
with the disease participated in the trial and were exposed to
the treatment. Bernard and colleagues described the design and
implementationofinstitutionbasedprospectiveinceptioncohort
studies in pediatric thrombosis and stroke research.
41
Discussion
In this review of methods that have been proposed for and used
to study health outcomes in rare diseases, we identified a wide
variety of non-traditional approaches. The majority of the
identified articles were published in 2008 or later, highlighting
the increasing interest in this area. Most articles also focused
on innovations in methods for clinical trials intended to
minimize the number of participants needed to meet the study
goalsortomaximizetheproportionofparticipantswhoreceive
active treatment to encourage enrollment.
Implications for randomized trials
Advances in clinical trial design relevant to rare diseases are
well developed, having been discussed in several technical
articles and applied in many clinical scenarios. Cornu and
colleagues provide examples of studies that have used each of
12 different randomized designs in the setting of rare diseases.
17
TheyandGuptaandcolleagueshavealsoproposedframeworks
toaidselectionofrandomizedclinicaltrialmethodsforstudying
health outcomes in rare diseases.
16 17 Both algorithms pose
similar questions to address whether the assumptions of
crossover and n-of-1 trials are likely to hold, such as whether
the intervention of interest has only a short term effect on the
outcome. Gupta and colleagues’ algorithm asks about whether
sufficient numbers of patients are likely to be recruited for a
given design and offers alternatives when this is not the case.
Cornu and colleagues’ algorithm explicitly asks about whether
objectivesofthestudyincludeminimizingthetimepatientsare
receiving placebo or ensuring that patients receive active
treatment by the end of the trial. Until a unified framework is
developed, both algorithms can be used to help decide the most
appropriate design to study health outcomes in patients with
rare diseases.
Implications for observational studies
In addition to dealing with considerations about general design
and analysis (for example, outcome selection, incorporation of
evidence into larger context), our methodological review is the
first to go beyond randomized trial methods for studying rare
diseases. This is important because in small sample sizes,
randomization will not always achieve its goal of balancing
patient characteristics between treatment groups. In contrast
with the body of literature on clinical trial methods in rare
diseases, however, the literature on observational methods is
considerablylessmature.Severalobservationalstudiespresented
only descriptive frequencies of outcomes after a treatment and
often with no comparison group, limiting the inferences that
can be drawn about the treatment and subsequent outcomes. In
general, observational studies of rare diseases used the same
methodsthatareusedtostudyhealthoutcomesinmorecommon
conditions. However, several advanced observational methods
that are used to study outcomes in common
conditions—including propensity scores and self controlled
designs—are particularly well suited for tackling confounding
in the setting of rare events. Propensity scores deal with
confounding in between person comparisons, whereas self
controlled designs implicitly tackle time invariant confounding
by making within person comparisons. It is important to note,
however, that statistically controlling for confounding may not
always be possible, even with propensity scores in studies with
few participants.
In addition to the often small samples, studies of patient health
outcomes in rare diseases using observational data face other
importantchallenges.Forexample,thereisoftennoappropriate
groupagainstwhichtocompareoutcomefrequenciesinpatients
with rare diseases and, even when there is, controlling for
confounding can be difficult because the risk factors of those
outcomes are usually not well understood. Yet, little work has
been done to develop or apply methods to directly deal with
these challenges. We did not identify any novel observational
methods that have been developed to study outcomes in rare
diseases. As observational data on rare diseases become more
ubiquitous, greater attention is needed on methods to analyze
these data to validly evaluate health outcomes in patients with
rare diseases.
Limitations of this study
This survey of research methods for rare diseases has several
limitations.Firstly,ourliteraturesearchwasfocusedonarticles
that mentioned “rare disease” in a searchable field. Because of
the large number of unique rare diseases, we were not able to
search for applications of innovative methods related to each
specificdisease.Inaddition,ourreviewwasintendedtoprovide
a general overview of non-traditional methods that have been
proposed or applied to studying rare diseases. If other
non-traditional methods exist that might be applicable to rare
diseases but have not yet been discussed in a publication in the
databases we searched, we may not have identified them.
Moreover, our review is intended to enhance awareness of the
availability and use of innovative methods for studying health
outcomes in rare diseases and is not intended to provide a
technical review of these methods, which can be found in the
cited references. Finally, while we searched three databases,
twoofwhichincludebiomedicaljournalsandathirdthatcovers
disciplines including psychology, physics, and engineering, it
ispossiblethatwemissedrelevantmethodsthathavebeenused
in other specialties, such as the social sciences.
Conclusions and future directions
Despitetheselimitations,wefoundseveralpromisingstrategies
that may contribute substantial advances to the study of health
outcomes in patients with rare diseases. Some of these methods
(for example, crossover designs and propensity scores) are
already used in studies of common conditions. Awareness of
the armamentarium of research tools available will help
investigatorsdesignstudiesinpatientswithspecificrarediseases
and will help clinicians interpret the results of these studies
when treating patients with these conditions. Observational
studiesareanimportantapproachforstudyinghealthoutcomes
in rare diseases, particularly as patient registries and electronic
healthcare databases continue to grow and offer richer clinical
information. However, greater attention to innovative methods
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RESEARCHfor using observational data to study rare disease health
outcomes is needed.
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RESEARCHWhat is already known on this topic
Many barriers exist to advancing knowledge of and treatment options for rare diseases
Because rare diseases are clinically dissimilar, clinicians, scientists, and other stakeholders working in one medical specialty may not
be familiar with methods being applied in other disciplines
What this study adds
Several promising strategies that may contribute substantial advances to the study of health outcomes in patients with rare diseases
have been proposed, particularly for randomized trials
Greater attention to innovative methods for using observational data to study rare disease health outcomes is needed
Tables
Table 1| Summary of research strategies for studying rare diseases and their advantages
Promote recruitment and
retention Address small Nos of patients and outcomes
Description Strategy
Expand
access to
studies and
participants
MaximizeNo
of
participants
who receive
treatment
Facilitate
confounding
adjustment
with sparse
data
Maximize
outcome
information
among
participants
Make use of
conventionally
underpowered
studies
MinimizeNo
of required
participants
Study design options:
— — — — — X Two or more treatments can be
simultaneously compared in a single group
of study participants
Factorial designs
— X — — — X Increases participants’ probability of being
exposed to more effective treatment and
reduces total sample size
Response-adaptive
randomization
— — — — — X Can identify differences in treatments
before the end of planned enrollment
Sequential designs
— X X — — X Using patients as their own controls both
guarantees treatment and increases
statistical efficiency
Crossover, n-of-1,
alternating designs
— — — X — — As compared with binary outcome,
continuous measures increase statistical
efficiency
Use continuous outcome
— — — X — — Can be measured before patients are lost
to follow-up for hard clinical endpoints
Use surrogate outcome
— — — X — — Combining multiple outcomes into a single
endpoint increases number of events
Use composite outcome
— — — X — — Allowing patients to contribute more than
one event can increase total number of
events
Use repeated measure
outcome
— — — X — — Longer studies permit capture of more
outcome events among participants
Increase duration of
follow-up
— — — — — — Reduces study size by sampling a portion
of patients who do not experience an
outcome
Case-control sampling
Recruitment and
enrollment strategies:
— — — X — — Outcomes are more likely to occur in high
risk patients
Focus on high risk
patients
X — — — — — Infrastructure for multicenter studies can
permit recruitment of larger and
geographically diverse groups of patients
Trial networks and
distributed data networks
Statistical options:
— — — — X — Small patient populations may preclude
sample sizes with sufficient power to
detect effects using conventional
thresholds
Increase α
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RESEARCHTable 1 (continued)
Promote recruitment and
retention Address small Nos of patients and outcomes
Description Strategy
Expand
access to
studies and
participants
MaximizeNo
of
participants
who receive
treatment
Facilitate
confounding
adjustment
with sparse
data
Maximize
outcome
information
among
participants
Make use of
conventionally
underpowered
studies
MinimizeNo
of required
participants
— — X — — — Can permit adjustment for more potential
confounders than outcome regression
modeling
Propensity scores
Incorporation into larger
evidence context:
— — — — X — Individual small studies may not provide
definitive evidence about a question, but
can be combined to yield sufficient power
Conduct study as part of
prospectively planned
meta-analysis
— — — — X — Small studies can help increase the
certainty around a clinical question
Incorporate study into
bayesian framework
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6802 doi: 10.1136/bmj.g6802 (Published 24 November 2014) Page 8 of 10
RESEARCHTable 2| Selected observational studies of health outcomes in patients with rare diseases
Methodological approach Outcome
No of
patients Study objective Rare condition
Lead author,
reference No
Used patient reported perceptions of
drug effectiveness for ALS symptoms
and compared this with survey based
physician perceptions
Concordance between patient
and clinician perceptions
4375 Compare clinicians’ and patients’
perspectives on symptomatic treatment
Amyotrophic lateral
sclerosis (ALS)
Nakamura
42
Matched lithium users to non-users and
followed for improvements in disease
progression
Change in the revised ALS
functional rating scale
447 Investigate whether off-label treatment
with lithium slows disease progression of
disease
ALS Wicks
43
Used linked electronic information
system to study outcomes in patients
with rare diseases
Incidence and clinical features
of Creutzfeldt-Jakob disease
115 Determine incidence of Creutzfeldt-Jakob
disease in Veterans Health Administration
and describe clinical features
Creutzfeldt-Jakob
disease
Barash
44
Used descriptive statistics,
Kaplan-Meier plot, and multivariable
time to event model
Overall survival, disease-free
survival, locoregional control
66 Assess rates, time, and sites of
recurrence for patients with endometrial
stromal sarcomas
Endometrial stromal
cancers
Schick
45
Proposed risk-set matching to reduce
selection bias in case-control studies
Splenectomy 4980 Compare odds of splenectomy in patients
with and without avascular necrosis
Gaucher disease Cole
28
Proposed use of claims data for
observational studies in rare diseases
Corticosteroid withdrawal 103 Examine incidence and predictors of
corticosteroid withdrawal in giant cell
arteritis
Giant cell arteritis Pugnet
46
Prospectively measured disease
activity and patient reported health
outcomes
Patient characteristics, clinical
features over time, and drug
use over time
122 Identify epidemiological, clinical, and
laboratory characteristics of juvenile
dermatomyositis
Juvenile
dermatomyositis
McCann
47
Used descriptive statistics,
Kaplan-Meier plot, and multivariable
time to event model
Overall survival, disease-free
survival, locoregional and local
control
77 Assess outcomes in patients with
olfactory neuroblastoma
Olfactory
neuroblastoma
Ozsahin
48
Described clinical course with respect
to changes in clinical features and
treatments
Patient characteristics, clinical
features over time, and drug
use over time
23 Describe characteristics of patients in
Swiss pulmonary arterial hypertension
registry
Pulmonary arterial
hypertension
Fasnacht
49
Used
pre-observational/post-observational
design
Change in prevalence of 20
different conditions
47 Compare prevalence of clinical conditions
related to disease of interest before and
after surgery among patients with
tuberous sclerosis complex
Subependymal giant
cell astrocytomas
Sun
50
Described outcomes in patients after
surgery
Diagnosis, repeated surgeries,
surgical complications
47 Examine outcomes after resection of
disease of interest among patients with
tuberous sclerosis complex
Subependymal giant
cell astrocytomas
Sun
51
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RESEARCHFigure
PRISMA flow diagram
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6802 doi: 10.1136/bmj.g6802 (Published 24 November 2014) Page 10 of 10
RESEARCH